The test-negative design for estimating influenza vaccine effectiveness
- PMID: 23499601
- DOI: 10.1016/j.vaccine.2013.02.053
The test-negative design for estimating influenza vaccine effectiveness
Abstract
Objective: The test-negative design has emerged in recent years as the preferred method for estimating influenza vaccine effectiveness (VE) in observational studies. However, the methodologic basis of this design has not been formally developed.
Methods: In this paper we develop the rationale and underlying assumptions of the test-negative study. Under the test-negative design for influenza VE, study subjects are all persons who seek care for an acute respiratory illness (ARI). All subjects are tested for influenza infection. Influenza VE is estimated from the ratio of the odds of vaccination among subjects testing positive for influenza to the odds of vaccination among subjects testing negative.
Results: With the assumptions that (a) the distribution of non-influenza causes of ARI does not vary by influenza vaccination status, and (b) VE does not vary by health care-seeking behavior, the VE estimate from the sample can generalized to the full source population that gave rise to the study sample. Based on our derivation of this design, we show that test-negative studies of influenza VE can produce biased VE estimates if they include persons seeking care for ARI when influenza is not circulating or do not adjust for calendar time.
Conclusions: The test-negative design is less susceptible to bias due to misclassification of infection and to confounding by health care-seeking behavior, relative to traditional case-control or cohort studies. The cost of the test-negative design is the additional, difficult-to-test assumptions that incidence of non-influenza respiratory infections is similar between vaccinated and unvaccinated groups within any stratum of care-seeking behavior, and that influenza VE does not vary across care-seeking strata.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Comment in
-
Is it necessary to adjust for calendar time in a test negative design?: Responding to: Jackson ML, Nelson JC. The test negative design for estimating influenza vaccine effectiveness. Vaccine 2013;31(April (17)):2165-8.Vaccine. 2014 May 23;32(25):2942. doi: 10.1016/j.vaccine.2013.08.048. Epub 2013 Sep 7. Vaccine. 2014. PMID: 24016812 No abstract available.
Similar articles
-
A comparison of the test-negative and the traditional case-control study designs for estimation of influenza vaccine effectiveness under nonrandom vaccination.BMC Infect Dis. 2017 Dec 8;17(1):757. doi: 10.1186/s12879-017-2838-2. BMC Infect Dis. 2017. PMID: 29216845 Free PMC article.
-
The case test-negative design for studies of the effectiveness of influenza vaccine.Vaccine. 2013 Jun 26;31(30):3104-9. doi: 10.1016/j.vaccine.2013.04.026. Epub 2013 Apr 23. Vaccine. 2013. PMID: 23624093
-
On the bias of estimates of influenza vaccine effectiveness from test-negative studies.Vaccine. 2017 Dec 19;35(52):7297-7301. doi: 10.1016/j.vaccine.2017.10.107. Epub 2017 Nov 13. Vaccine. 2017. PMID: 29146382 Free PMC article.
-
Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies.Lancet Infect Dis. 2016 Aug;16(8):942-51. doi: 10.1016/S1473-3099(16)00129-8. Epub 2016 Apr 6. Lancet Infect Dis. 2016. PMID: 27061888 Review.
-
Challenges in estimating influenza vaccine effectiveness.Expert Rev Vaccines. 2019 Jun;18(6):615-628. doi: 10.1080/14760584.2019.1622419. Epub 2019 May 31. Expert Rev Vaccines. 2019. PMID: 31116070 Free PMC article. Review.
Cited by
-
Anti-SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021-June 2022.J Infect Dis. 2024 Jul 25;230(1):45-54. doi: 10.1093/infdis/jiae090. J Infect Dis. 2024. PMID: 39052724 Free PMC article.
-
Effectiveness of Influenza Vaccination During Pregnancy Against Laboratory-Confirmed Seasonal Influenza Among Infants Under 6 Months of Age in Ontario, Canada.J Infect Dis. 2024 Jul 25;230(1):e80-e92. doi: 10.1093/infdis/jiad539. J Infect Dis. 2024. PMID: 39052720 Free PMC article.
-
Hypothesis testing and sample size considerations for the test-negative design.BMC Med Res Methodol. 2024 Jul 16;24(1):151. doi: 10.1186/s12874-024-02277-4. BMC Med Res Methodol. 2024. PMID: 39014324 Free PMC article.
-
Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.Vaccine. 2024 Jul 25;42(19):3931-3937. doi: 10.1016/j.vaccine.2024.05.067. Epub 2024 Jun 4. Vaccine. 2024. PMID: 38839521 Free PMC article.
-
Transmission risks of Omicron BA.5 following inactivated COVID-19 vaccines among children and adolescents in China.Commun Med (Lond). 2024 May 18;4(1):92. doi: 10.1038/s43856-024-00521-y. Commun Med (Lond). 2024. PMID: 38762678 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical